CANbridge Pharmaceuticals, Inc. (1228.HK) is delighted to announce that long-term follow up data from the Phase 1/2 study of CAN008 (asunercept) plus temozolomide/radiotherapy (TMZ/RT) in newly diagnosed glioblastoma multiforme (GBM) has revealed an impressive long-term survival rate of 67% at five years, three years after the trial ended!
The data will be presented as a poster at the European Society of Medical Oncologists (ESMO) Sarcoma and Rare Cancers Annual Congress, March 20-22, in Lugano, Switzerland. Conducted at Chang Gung Memorial Hospital, Taoyuan, Taiwan, the study was led by Wei Kuo-Chen MD, Professor, formerly at Chang Gung Memorial Hospital and now at New Taipei City Tucheng Hospital. This breakthrough research is a testament to CANbridge’s commitment to the research, development and commercialization of transformative therapies to treat rare diseases and oncology.
In the CAN008 Phase 1/2 trial, four out of nine newly diagnosed glioblastoma multiforme patients in the high dose cohort (400mg) were alive at the five-year follow-up, three years after the trial completion.
This remarkable 83% two-year survival rate is more than twice the institutional GBM database’s 34.3%, and the median progression-free survival of 17.95 months is more than double the historical median of 6.9 months for GBM patients receiving standard-of-care treatment. Moreover, the study found that a high tumor mutation burden and DNAH family gene mutation were linked to favorable responses to CAN008 treatment.
CAN008, a treatment under investigation to battle glioblastoma multiforme (GBM), is currently undergoing a Phase 2 clinical trial in China. Hopes are high, as mid-2023 is projected to bring an interim analysis of the trial’s data.
CANbridge’s CAN008 has delivered promising results in glioblastoma multiforme, one of the deadliest cancers with dismal survival rates. Chief Medical Officer Gerry Cox, M.D., Ph.D., and a study author, reports that CAN008 patients showed an impressive median progression-free-survival of 17.95 months—more than double the historical median PFS for standard-of-care GBM patients—and that 67% of high-dose patients were alive after five years. These results are a shining light of hope in a field with few treatment advances and a high unmet medical need.
CANbridge is thrilled to report a five-year survival rate of patients in their CAN008 Phase 1/2 trial, three years after its completion, in glioblastoma multiforme, a cancer with typically poor outcomes. Lead candidate CAN008 is currently in a Phase 2 GBM trial in China, and CANbridge is committed to bringing this potentially new and promising treatment to brain cancer patients. Founder, Chairman and CEO James Xue, Ph.D. said, “We are extremely encouraged by these results and look forward to the continued development of CAN008.”
About CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc. (HKEX:1228) is a global biopharmaceutical company with a mission to develop transformative therapies for rare diseases and rare oncology. With three approved drugs and a pipeline of 10 potential treatments, CANbridge strives to address the needs of those suffering from Hunter syndrome, complement-mediated disorders, hemophilia A, metabolic disorders, rare cholestatic liver diseases, neuromuscular diseases, and glioblastoma multiforme.
To further this mission, CANbridge has opened the Next-Generation Innovation and Process Development Facility, which is developing gene therapies with the potential to cure Pompe disease, Fabry disease, spinal muscular atrophy (SMA) and other neuromuscular conditions. Animal data from the SMA gene therapy has already been presented at the American Society for Gene and Cell Therapy (ASGCT), the European Society for Gene and Cell Therapy (ESGCT), and the World Muscle Congress. CANbridge partners with world-leading researchers and biotech companies such as Apogenix, GC Pharma, Mirum, Wuxi Biologics, Privus, UMass Chan Medical School, the University of Washington School of Medicine, and Scriptr Global.